text_1: 在 本 试验 期间 发生 疾病 进展 的 患者 中 , 纳武利 尤 单抗 + 伊匹 单抗 组 44.0% 的 患者 和 化疗 组 56.3% 的 患者 接受 了 后续 全身性 治疗 ; 化疗 组 42.8% 的 患者 中 接受 了 免疫治疗 .
  
text_2: among the patients who had disease progression during the trial , subsequent systemic therapy was administered in 43.6 % of the patients who had received nivolumab plus ipilimumab and in 55.8 % of those who had received chemotherapy ; immunotherapy was administered in 42.4 % of those in the chemotherapy group .
  